Clinical Trial Update: A Long-term Administration Trial of SEP-363856 in Patients With Schizophrenia [Phase 3]

View source ↗

Summary

This is a Phase 3 long-term administration trial of SEP-363856 in patients with schizophrenia that is currently recruiting, sponsored by Otsuka.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Schizophrenia

Drugs mentioned

• SEP-363856

Snippet

Sponsor: Otsuka Pharmaceutical Co., Ltd. | Conditions: Schizophrenia | Phase 3 | Status: RECRUITING